Patients must not be candidates for allogeneic hematopoietic stem cell transplant; NOTE: Subjects up to age 70 years who are considered fit for allogeneic hematopoietic stem cell transplant, should be considered for enrollment on E1910, in order to avoid competing with that study; if a patient is considered unfit for intensive chemotherapy at the time of initial diagnosis, but subsequently achieves a complete remission (CR), then it will be left to the treating physician’s discretion to consider hematopoietic stem cell transplant (HSCT)
ELIGIBILITY CRITERIA - PHASE II (ARM D): Patient may be enrolled with a prior allogeneic hematopoietic stem cell transplant (HSCT) but the transplant date must be at least 90 days before date of enrollment; patient must be off immunosuppression and without active GVHD prior to enrollment if previous HSCT
Gene therapy using an integrating vector Allogeneic hematopoietic stem cell transplant at any time not permitted
Prior allogeneic hematopoietic cell transplant
Subjects with prior autologous and allogeneic hematopoietic stem cell transplantation (allo HSCT) are eligible.
Intention to proceed to high dose chemotherapy (HDT) and autologous hematopoietic stem cell transplant (HSCT)
Adult male and female subjects at least 18 years of age who have had allogenic bone marrow transplant (BMT) or hematopoietic stem cell transplantation (HSCT).
Prior allogeneic hematopoietic stem cell transplantation (allo HSCT)
Prior allogeneic hematopoietic cell transplant
Previous allogeneic hematopoietic stem cell transplant
Allogeneic hematopoietic stem cell transplant
Prior allogeneic transplant for any hematopoietic disorder
Subject is a candidate for hematopoietic stem cell transplantation (HSCT).
Prior cell or gene therapy, excluding transfers of genetically unmodified autologous cells (eg. Hematopoietic stem cell transplantation), at any time; or prior allogeneic HSCT at any time
DONOR: Testing for communicable disease will be performed according to the University of Washington (UW) Hematopoietic Stem Cell Transplant Program guidelines set forth in the most current standard operating policies and procedures (UW Foundation for the Accreditation of Cellular Therapy [FACT]-accredited Clinical Hematopoietic Cell Processing Laboratory [CHCPL] standard of procedure [SOP]) for hematopoietic cell donor evaluation and selection
Immunosuppression following a Hematopoietic Stem Cell Transplantation (HSCT) within 6 weeks prior to study entry;
Allogeneic hematopoietic stem cell transplantation (HSCT) within 24 weeks before the start of protocol-specified therapy.
Either not eligible or unwilling to proceed with hematopoietic stem cell transplantation (HSCT)
Eligible for, have a suitable donor, and are willing to undergo hematopoietic stem cell transplantation (HSCT)
Previous allogeneic hematopoietic cell transplant (HCT)
History of hematopoietic stem cell transplant (HSCT)
Has previously received an allogeneic hematopoietic cell transplant or chimeric antigen receptor-modified (CAR)-T cells
Diagnosis of AML and MDS according to World Health Organization (WHO) classification that underwent first allogeneic hematopoietic cell transplant (HSCT) with either peripheral blood or bone marrow as the source of the hematopoietic stem cells
Prior allogeneic hematopoietic cell transplant.
Has received allogeneic hematopoietic stem cell transplant within 3 months of CAR T cell infusion; hematopoietic stem cell transplant (HSCT) > 3 months from CAR T cell infusion eligible
Individuals who are eligible for allogeneic hematopoietic stem cell transplantation (HSCT) as determined by the treating physician, and have a suitable donor or appropriate stem cell source available
Study enrollment no earlier than 3 months after preceding hematopoietic cell transplantation (HSCT)
Patients who have received a prior allogeneic hematopoietic stem cell transplant (HSCT) and who have either rejected their grafts or who have become tolerant of their grafts with no active GVHD requiring immunosuppressive therapy
Prior autologous or allogeneic hematopoietic stem cell
Preceding allogeneic hematopoietic stem cell transplant (HSCT)
-  Participant is not a candidate to undergo intensive chemotherapy or allogeneic hematopoietic stem cell transplantation (HSCT).
Malignant conditions or other life threatening disorders correctable by transplant for which CD34+ selected, T-cell depleted allogeneic hematopoietic stem cell transplantation is indicated such as:
No subjects who have received an allogeneic hematopoietic stem cell transplant are eligible
Received an allogeneic hematopoietic transplant within 3 months of screening
Have active malignancy with the exception of nonmelanoma skin cancer. Subjects who have had a hematopoietic stem cell transplant (HSCT) and who experience relapse or progression of the malignancy as per investigator's opinion are not to be enrolled.
Evidence of multiple myeloma disease progression (as defined by IMWG) any time prior to autologous (auto)-hematopoietic stem cell transplant (HSCT)
Prior autologous or allogeneic hematopoietic stem cell transplantation (HSCT)
Prior allogeneic transplant for any hematopoietic disorder
Subject is refractory to or relapsed after first-line AML therapy (with or without hematopoietic stem cell transplant (HSCT)).
Hematopoietic cell transplantation (At least 60 days from infusion of hematopoietic cells prior to first dose of tazemetostat)
Prior allogeneic hematopoietic stem cell transplant.
Subject who has history of organ transplant or allogeneic hematopoietic stem cell transplantation.
Subjects with relapsed primary disease, or subjects who have been treated for relapse after the allogeneic hematopoietic stem-cell transplantation (allo-HSCT) was performed.
Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ? 6 months.
Patients who have previously undergone allogeneic hematopoietic stem cell transplant will be excluded from this study
The patient has received any hematopoietic stem cell transplantation (HSCT) ? 3 months prior to start of Investigational Product.
Allogeneic hematopoietic stem cell transplant within 100 days prior to leukapheresis
Prior history of allogeneic hematopoietic stem cell transplant (HSCT).
Recipients of prior allogeneic hematopoietic stem cell transplant (HSCT) with active acute or chronic GVHD
Prior allogeneic hematopoietic stem cell transplant
Prior allogeneic hematopoietic stem cell transplant
Hematopoietic stem cell transplant (HSCT) patients with symptomatic hemorrhagic cystitis (minimal grade 1 symptoms of HC per NCI criteria) and positive BKV in urine > 1 x 10^3 deoxyribonucleic acid (DNA) copies/ml
Recipient of an hematopoietic stem cell transplantation (HSCT)
Prior autologous or allogeneic hematopoietic stem cell transplant (HSCT)
Prior allogeneic hematopoietic stem cell transplant.
Prior allogeneic hematopoietic stem cell transplant (HSCT)
Prior allogeneic hematopoietic stem cell transplant
Patient must not be a candidate for an allo-hematopoietic stem cell transplant (HSCT)
At least 100 days after receiving any allogeneic hematopoietic stem cell transplant AND
Previous allogeneic hematopoietic stem cell transplant (HSCT transplant).
Allogeneic hematopoietic stem cell transplant or Donor Lymphocyte Infusion within 90 days prior to to the first dose of study drug
Prior allogeneic hematopoietic stem cell transplant
Prior allogeneic hematopoietic stem cell transplant within </=4 months before first dose of study drug (Subjects must have completed immunosuppressive therapy before enrollment.
Patients must be within 30 – 120 days after hematopoietic stem cell transplant (HSCT)
At least 60 days must have elapsed from hematopoietic stem cell transplantation (HSCT)
Subject has had hematopoietic stem cell transplant (HSCT) and meets any of the following:
Allogeneic hematopoietic stem cell transplantation (HSCT) within 12 weeks before blinatumomab treatment
Histologically confirmed (Myelodysplastic Syndromes) MDS or Acute Myeloid Leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (HSCT) with either peripheral blood or bone marrow as the source of hematopoietic stem cells At the time of allogeneic HSCT:
Prior allogeneic hematopoietic cell transplant
Not currently a candidate for allogeneic hematopoietic stem cell transplant (HSCT).
Previous allogeneic hematopoietic transplant within 90 days of study enrollment, Active GVHD requiring treatment.
Previous allogeneic hematopoietic transplant within 90 days. Active GVHD requiring treatment
Any previous allogeneic hematopoietic stem cell transplant.
Subject is not a candidate to undergo allogenic hematopoietic stem cell transplantation (HSCT).
Adults undergoing hematopoietic stem cell transplantation (HSCT) at the University of Wisconsin Carbone Cancer Center (UWCCC)
Scheduled to undergo an allogeneic hematopoietic stem cell transplant for any cancer or non-cancer illness
Patient has CMV specific T-cells from the donor of his/her hematopoietic stem cell transplantation (HSCT) available
Prior allogeneic hematopoietic stem cell transplant (HSCT)
Allogeneic hematopoietic cell transplant recipient
Undergoing hematopoietic stem cell transplantation (HSCT) at the University of Wisconsin Carbone Cancer Center (UWCCC)
Prior allogeneic hematopoietic cell transplant
Patients with previous hematopoietic stem cell transplant (HSCT)
Diagnosis of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for whom an allogeneic hematopoietic stem cell transplant using a reduced intensity conditioning is planned or has been performed and patient is prior to day 100 post-transplant
Subjects undergoing matched related full intensity allogeneic hematopoietic stem cell transplantation (HSCT)
Patient must have a diagnosis that is managed with an alternative donor allogeneic hematopoietic cell transplant
Prior allogeneic hematopoietic stem cell transplant.
Prior treatment with any adoptive T cell therapy; prior hematopoietic stem cell transplant (HSCT) is allowed
Has documented seropositivity for CMV within 1 year before hematopoietic stem cell transplant (HSCT)
Has received hematopoietic stem cell transplantation (HSCT) within 60 days of the first dose of DS-3201b
Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ? 6 months prior to starting CC-90009.